• Patent Title: Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting
  • Application No.: US15261890
    Application Date: 2016-09-10
  • Publication No.: US10238758B2
    Publication Date: 2019-03-26
  • Inventor: Yubin Miao
  • Applicant: STC.UNM
  • Applicant Address: US NM Albuquerque
  • Assignee: STC.UNM
  • Current Assignee: STC.UNM
  • Current Assignee Address: US NM Albuquerque
  • Agent Henry D. Coleman; R. Neil Sudol
  • Main IPC: A61K51/00
  • IPC: A61K51/00 A61M36/14 A61K51/08 C07K7/56 A61K38/17 A61K38/00
Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting
Abstract:
The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue, suggesting favorable selective activity of compounds according to the present invention, which can be used as effective therapeutic agents against melanoma, including metastatic melanoma. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are useful to initiate therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic and therapeutic tools for a number of conditions and diseases states, especially melanoma.
Information query
Patent Agency Ranking
0/0